Fortress Biotech, Inc. (FBIO) Cash Flow Statement
Where FBIO’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$65.8M
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$65.8M −104.0% margin
- Returned to shareholders
- $929,000
- Change in cash
- $21.8M cash at year-end $80.6M
Cash from operations
−$65.8M
Acquisitions & other
+$10.1M
Dividends
−$664,000
Share buybacks (net)
−$265,000
Net borrowing (repayment)
−$5.6M
Shares issued
+$81.7M
Other financing
+$2.3M
Change in cash
$21.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
FBIO operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
FBIO cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$45.8M2016 | −$65.8M2025 | — | |
| Capital expenditures | $10.5M2016 | $02025 | −100.0% | |
| Free cash flow | −$56.3M2016 | −$65.8M2025 | — | |
| Free cash flow margin | −341.7%2016 | −104.0%2025 | +237.8 pts | |
| Stock-based compensation | $12.1M2016 | $28.7M2025 | +10.1%/yr | |
| Dividends paid | $299,0002016 | $664,0002025 | +9.3%/yr | |
| Share buybacks (net) | $02016 | $265,0002025 | — | |
| Capex / revenue | 63.7%2016 | 0.0%2025 | −63.7 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
FBIO cash flow by activity
OperatingInvestingFinancingChange in cash
FBIO net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
FBIO cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$32.9M | −$120.9M | −$154.2M | −$213.9M | −$164.8M | −$103.0M | −$101.7M | −$130.8M | −$99.8M | −$71.3M |
| Depreciation & amortization | $4.7M | $4.5M | $6.0M | $9.4M | $6.8M | $5.3M | $4.7M | $2.1M | $1.3M | $1.1M |
| Stock-based compensation | $28.7M | $32.6M | $17.0M | $23.0M | $19.5M | $13.5M | $13.2M | $15.0M | $14.0M | $12.1M |
| Change in working capital | −$25.1M | −$8.1M | −$12.5M | −$715,000 | $36.4M | −$4.8M | −$4.8M | $5.7M | −$2.2M | $2.0M |
| Other non-cash items | −$41.2M | $11.7M | $15.4M | $2.9M | −$14.4M | $5.3M | −$6.3M | $9.1M | $1.4M | $10.3M |
| Cash from operating activities | −$65.8M | −$80.2M | −$128.2M | −$179.4M | −$116.5M | −$83.7M | −$95.0M | −$98.8M | −$85.4M | −$45.8M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$15.0M | −$8.1M | −$3.1M | −$16.3M | −$7.2M | −$9.4M | −$9.4M | −$5.4M | −$10.5M |
| Investments (net) | — | −$15.0M | −$2.4M | −$22.9M | $56.9M | −$7.2M | $17.6M | $52.6M | −$41.6M | −$6.1M |
| Acquisitions & other investing | $10.1M | $15.0M | $8.4M | $3.1M | $0 | $7.2M | $11.9M | −$24.4M | $5.4M | $10.5M |
| Cash from investing activities | $10.1M | −$15.0M | −$2.1M | −$22.9M | $40.5M | −$7.2M | $20.1M | $18.8M | −$41.6M | −$6.1M |
| Financing activities | ||||||||||
| Dividends paid | −$664,000 | −$4.7M | −$8.8M | −$8.8M | −$8.8M | −$6.8M | −$2.6M | −$2.3M | −$299,000 | −$299,000 |
| Share repurchases & issuance (net) | −$265,000 | $0 | −$400,000 | −$1.2M | $24.3M | −$70,000 | −$24,000 | −$234,000 | $1.7M | $623,000 |
| Net borrowing (repayment) | −$5.6M | −$7.3M | −$38.8M | $49.2M | −$15.0M | −$29.7M | $14.7M | $1,000 | $37.2M | $6.1M |
| Shares issued | $81.7M | $82.8M | $71.0M | $43.0M | $172.2M | $224.9M | $144.2M | $38.4M | $0 | $0 |
| Other financing | $2.3M | −$163,000 | $9.7M | −$6.9M | −$23.7M | −$16.0M | −$9.7M | $14.8M | $111.8M | $36.4M |
| Cash from financing activities | $77.4M | $70.6M | $32.7M | $75.3M | $149.0M | $172.4M | $146.7M | $50.6M | $150.4M | $42.9M |
| Summary | ||||||||||
| Net change in cash | $21.8M | −$24.6M | −$97.6M | −$127.0M | $73.0M | $81.6M | $71.8M | −$29.4M | $27.1M | −$9.9M |
| Cash at end of period | $80.6M | $58.8M | $83.4M | $181.0M | $308.0M | $235.0M | $153.4M | $81.6M | $131.3M | $88.3M |
| Free cash flow | −$65.8M | −$95.2M | −$136.3M | −$182.5M | −$132.9M | −$90.8M | −$104.4M | −$108.2M | −$90.9M | −$56.3M |
| Free cash flow margin | −104.0% | −165.0% | −161.3% | −240.9% | −193.2% | −199.2% | −284.9% | −402.5% | −48.4% | −341.7% |
| Capex / revenue | 0.0% | 26.0% | 9.6% | 4.0% | 23.8% | 15.7% | 25.6% | 34.8% | 2.9% | 63.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$468,000 | $110.4M | −$5.4M | $8.8M | −$11.7M | −$24.7M | −$26.3M | −$26.7M | −$10.9M | −$39.0M | −$9.3M | −$10.7M |
| Depreciation & amortization | $1.1M | $1.7M | $1.2M | $1.2M | $1.2M | $1.7M | $1.6M | $3.3M | $1.2M | $1.2M | $1.7M | $2.8M |
| Stock-based compensation | $2.9M | $1.8M | $2.5M | $3.2M | $16.8M | $6.3M | $16.2M | $6.6M | $5.0M | $4.9M | $3.7M | $4.4M |
| Change in working capital | −$53.6M | $55.8M | −$10.8M | −$4.5M | −$6.8M | −$3.0M | −$5.7M | −$5.6M | −$3.2M | $5.7M | −$18.2M | −$8.3M |
| Other non-cash items | −$9.1M | $34.2M | $42,000 | −$14.8M | −$27.1M | $143,000 | $1.3M | $2.3M | −$13.9M | $1.9M | −$12.9M | −$4.9M |
| Cash from operating activities | −$59.3M | $203.9M | −$12.5M | −$6.1M | −$27.6M | −$19.6M | −$12.9M | −$20.1M | −$21.8M | −$25.4M | −$34.9M | −$16.8M |
| Investing activities | ||||||||||||
| Capital expenditures | −$79,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$63,000 | −$1.0M |
| Investments (net) | — | — | — | $2.9M | $6.1M | $1.2M | −$15.0M | $0 | $0 | $0 | −$63,000 | $5.0M |
| Acquisitions & other investing | $0 | — | $7.3M | $0 | $0 | $0 | $0 | — | — | — | $63,000 | $1.0M |
| Cash from investing activities | −$79,000 | — | $7.3M | $2.9M | $6.1M | $1.2M | −$15.0M | — | — | — | −$63,000 | $5.0M |
| Financing activities | ||||||||||||
| Dividends paid | −$141,000 | $0 | −$166,000 | −$166,000 | −$166,000 | −$166,000 | −$166,000 | −$176,000 | −$2.2M | −$2.2M | −$2.2M | −$2.2M |
| Share repurchases & issuance (net) | $0 | −$14.3M | $0 | $0 | −$115,000 | −$150,000 | — | $0 | −$2.6M | $0 | −$400,000 | $90,000 |
| Net borrowing (repayment) | $0 | −$14.5M | $0 | −$704,000 | −$4.9M | $0 | $5.0M | −$17.3M | — | — | — | — |
| Shares issued | $0 | $0 | $5.5M | $14.1M | $9.1M | $53.0M | $21.2M | $20.4M | $16.0M | $25.3M | $31.1M | $10.4M |
| Other financing | $232,000 | $1.4M | $412,000 | $1.8M | $619,000 | −$509,000 | −$217,000 | −$160,000 | $3.1M | $4.8M | $15.1M | −$11.0M |
| Cash from financing activities | $91,000 | −$27.4M | $5.7M | $15.1M | $4.5M | $52.1M | $25.8M | $2.7M | $14.3M | $27.9M | $43.6M | −$2.7M |
| Summary | ||||||||||||
| Net change in cash | −$59.3M | $176.5M | −$6.8M | $11.8M | −$17.0M | $33.7M | −$2.1M | −$17.3M | −$7.6M | $2.5M | $6.2M | −$14.5M |
| Cash at end of period | $196.6M | $257.1M | $80.6M | $87.4M | $75.6M | $92.6M | $58.8M | $60.9M | $78.3M | $85.8M | $80.9M | $74.7M |
| Free cash flow | −$59.4M | $203.9M | −$12.5M | −$6.1M | −$27.6M | −$19.6M | −$12.9M | −$20.1M | −$21.8M | −$25.4M | −$35.0M | −$17.8M |
| Free cash flow margin | −317.1% | 1,271.1% | −78.0% | −34.7% | −167.9% | −148.9% | −85.4% | −137.1% | −146.6% | −194.8% | −175.5% | −51.2% |
| Capex / revenue | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 2.9% |
| Operating cash flow / net income | — | 1.85 | — | −0.69 | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
FBIO cash generation
In fiscal 2025 (ended December 31, 2025), Fortress Biotech generated -$65.8 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$65.8 million, −104.0% of revenue. It returned $0.9 million to shareholders through dividends ($0.7 million) and net share buybacks ($0.3 million). Cash and equivalents rose by $21.8 million over the year.
Related: FBIO income statement, FBIO balance sheet. See the FBIO stock overview for the latest quote and news.
FBIO cash flow FAQ
What is Fortress Biotech's free cash flow?
Fortress Biotech's free cash flow was -$65.8 million in fiscal 2025: -$65.8 million of operating cash flow minus $0 of capital expenditures It was -$95.2 million a year earlier..
How much cash does Fortress Biotech generate from operations?
Fortress Biotech generated -$65.8 million of cash from operating activities in fiscal 2025.
How much stock does Fortress Biotech buy back?
Fortress Biotech spent $0.3 million on net share repurchases in fiscal 2025.
How much does Fortress Biotech pay in dividends?
Fortress Biotech paid $0.7 million in dividends in fiscal 2025.